

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/625,854
Filing Date	July 23, 2003
First Named Inventor	Andre DELACOURTE
Art Unit	1649
Examiner Name	Chang-Yu Wang
Attorney Docket Number	11362.0039.NPUS01

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
/CYW/	C17	CASAS, C., et al., "Massive CA 1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated A{beta} 42 Accumulation in a Novel Alzheimer Transgenic Model," <i>Am. J. Pathol.</i> (2004), 165:1289-1300.	
	C18	DELACOURTE, A., et al., "The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease," <i>Neurology</i> (1999), 52 :1158-1165.	
	C19	DELACOURTE, A., et al., "Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease," <i>Neurology</i> (2002), 59:398-407.	
	C20	DERAMECOURT, V., et al., "Biochemical staging of synucleinopathy and amyloid deposition in dementia with lewy bodies," <i>J Neuropathol. Exp. Neurol.</i> (2006), 65:278-288.	
	C21	SERGEANT, N., et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <i>Journal of Neurochemistry</i> (2003), 85:1581-1591.	
	C22	VANDERSTICHELE, H., et al., "Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment," <i>Clin. Chem.</i> (2005), 51:1650-1660.	
	C23	NICOLL, J.A., et al., "Abeta Species Removal After Abeta42 Immunization," <i>J. Neuropathol. Exp. Neurol.</i> (2006), 65:1040-1048.	
↓	C24	PATTON, R.L., et al., "Amyloid-{beta} Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients: A Biochemical Analysis," <i>Am. J. Pathol.</i> (2006), 169:1048-1063.	
/CYW/	C25	PICCINI, A., et al., "Beta amyloid is different in normal aging and in Alzheimer's disease," <i>J. Biol. Chem.</i> (2005), 280(40) :34186-34192.	

Examiner Signature	/Chang-Yu Wang/	Date Considered	05/08/2007
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.